AstraZeneca loses US appeal in generic Prilosec OTC patent dispute with Dr Reddy's
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit has rejected AstraZeneca's appeal of a lower court decision that Dr Reddy's Laboratories' generic version of Prilosec (omeprazole delayed-release) capsules OTC did not infringe two US patents, Nos 5,900,424 and 5,690,960. The product has final US FDA approval.